HPE Europe 2021
This year, recognising that as we are still unable to meet in person, we will be going ahead with two exclusive, virtual extended lunch time sessions. We will be joined by investors including key players from the private equity community, healthcare companies and operators, advisers and health industry experts. The combination will allow us to share their insights and strategies in shaping the future of healthcare and healthcare investing and discussing the latest and most important trends in HPE.
JOIN US IN CONVERSATION WITH DR. ALI PARSA
We are delighted to welcome Dr. Ali Parsa, CEO & Founder of Babylon Health, as our keynote speaker, in conversation with London Managing Partner Hamid Yunis.
Dr Parsa is a visionary healthcare engineer whose revolutionary AI and digital company is shaping the future of healthcare. Described as the UK’s healthtech giant, Babylon Health will go public in the US via SPAC. The merger with Alkuri Global Acquisition would give the combined company a pro forma equity value of $4.2bn.
Where do the Opportunities Exist?
The panel will share their perspectives on what opportunities exist for investors and recipients of investment in the healthcare sector. In particular, the effects of COVID-19 and what this means for the sector going forward.
Healthcare Financing Challenges and Opportunities During COVID and Beyond
The pandemic created both challenges in managing credit risk and opportunities to gain market share for lenders in the coming year. This panel of leading credit professionals will discuss the outlook for leveraged loan activity and trends in terms and pricing.
Health Services M&A in France, Germany and the United Kingdom
We explore each jurisdiction in a summarizing, comparative discussion with panelists from each country exploring the current and forecast situation in healthcare M&A.
Evaluating Value and Bridging Expectations in 2021 and Beyond
Given the competitive landscape, investing in healthcare companies is more complex, but potentially more lucrative, than ever. Our panelists will discuss valuations in the current market, opportunities for value creation in 2021 and beyond and the continued impact of COVID 19 and its implications for the healthcare PE community.
Investment Opportunities in Life Sciences
Perspectives on investment opportunities in life sciences companies as well as outsourcing providers in life sciences such as CMO, CRO and technology providers with a particular reference to the effects of COVID-19 and what this means for the sector going forward.
In Conversation
Hamid Yunis, Managing Partner McDermott London in conversation with Sylvester Oppong, Head of Healthcare Services Corporate Finance and M&A at EY and Dr. Michelle Tempest, Partner at Candesic Limited
In this session, Hamid, Sylvester and Michelle will discuss the key trends addressed over the past two days. We will also hear from both Sylvester and Michelle on the key trends they are seeing and what they think the next 6 months will look like in terms of healthcare strategy and investment.
McDermott Will & Emery is proud to partner with the European Healthcare Private Equity Association (EHCPEA), a new association representing funds with more than EUR150 billion invested in healthcare.
Grégoire Andrieux
Partner, Paris
Partner, London
Partner, Munich
Counsel, London
Partner, London
Aymen Mahmoud
Partner, London
Partner, Paris
Partner, Munich
Partner, Paris
Eleanor West
Partner, London
Partner, London
Partner, London
WEBINAR 1: WHERE DO THE OPPORTUNITIES EXIST?
WEBINAR 2: What are the life science transaction trends in the wake of the sanitary crisis?
WEBINAR 3: What is the future landscape for Innovation, Medtech and Digital Health in the post Covid world for health investors and providers?
WEBINAR 4: What’s the impact of recent regulation and government measures on investments in healthcare and life sciences in Europe?
WEBINAR 5: What impact has Coronavirus had on doing healthcare deals?
